TY - JOUR
T1 - Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR)
AU - Roehrig, Andrew
AU - Indelicato, Daniel J.
AU - Paulino, Arnold C.
AU - Ermoian, Ralph
AU - Hartsell, William
AU - Perentesis, John
AU - Hill-Kayser, Christine
AU - Lee, Jae Y.
AU - Laack, Nadia N.
AU - Mangona, Victor
AU - MacEwan, Iain
AU - Eaton, Bree R.
AU - Gallotto, Sara
AU - Bajaj, Benjamin V.M.
AU - Aridgides, Paul D.
AU - Yock, Torunn I.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/4
Y1 - 2023/4
N2 - Purpose: Atypical teratoid/rhabdoid tumors (ATRT) of the central nervous system (CNS) are rare tumors with a poor prognosis and variable use of either focal or craniospinal (CSI) radiotherapy (RT). Outcomes on the prospective Pediatric Proton/Photon Consortium Registry (PPCR) were evaluated according to RT delivered. Methods: Pediatric patients receiving RT were prospectively enrolled on PPCR to collect initial patient, disease, and treatment factors as well as provide follow-up for patient outcomes. All ATRT patients with evaluable data were included. Kaplan–Meier analyses with log-rank p-values and cox proportional hazards regression were performed. Results: The PPCR ATRT cohort includes 68 evaluable ATRT patients (median age 2.6 years, range 0.71–15.40) from 2012 to 2021. Median follow-up was 40.8 months (range 3.4–107.7). Treatment included surgery (65% initial gross total resection or GTR), chemotherapy (60% with myeloablative therapy including stem cell rescue) and RT. For patients with M0 stage (n = 60), 50 (83%) had focal RT and 10 (17%) had CSI. Among patients with M + stage (n = 8), 3 had focal RT and 5 had CSI. Four-year overall survival (OS, n = 68) was 56% with no differences observed between M0 and M + stage patients (p = 0.848). Local Control (LC) at 4 years did not show a difference for lower primary dose (50–53.9 Gy) compared to ≥ 54 Gy (73.3% vs 74.7%, p = 0.83). For patients with M0 disease, four-year OS for focal RT was 54.6% and for CSI was 60% (Hazard Ratio 1.04, p = 0.95. Four-year event free survival (EFS) among M0 patients for focal RT was 45.6% and for CSI was 60% (Hazard Ratio 0.71, p = 0.519). For all patients, the 4-year OS comparing focal RT with CSI was 54.4% vs 60% respectively (p = 0.944), and the 4-year EFS for focal RT or CSI was 42.8% vs 51.4% respectively (p = 0.610). Conclusion: The PPCR ATRT cohort found no differences in outcomes according to receipt of either higher primary dose or larger RT field (CSI). However, most patients were M0 and received focal RT. A lower primary dose (50.4 Gy), regardless of patient age, is appealing for further study as part of multi-modality therapy.
AB - Purpose: Atypical teratoid/rhabdoid tumors (ATRT) of the central nervous system (CNS) are rare tumors with a poor prognosis and variable use of either focal or craniospinal (CSI) radiotherapy (RT). Outcomes on the prospective Pediatric Proton/Photon Consortium Registry (PPCR) were evaluated according to RT delivered. Methods: Pediatric patients receiving RT were prospectively enrolled on PPCR to collect initial patient, disease, and treatment factors as well as provide follow-up for patient outcomes. All ATRT patients with evaluable data were included. Kaplan–Meier analyses with log-rank p-values and cox proportional hazards regression were performed. Results: The PPCR ATRT cohort includes 68 evaluable ATRT patients (median age 2.6 years, range 0.71–15.40) from 2012 to 2021. Median follow-up was 40.8 months (range 3.4–107.7). Treatment included surgery (65% initial gross total resection or GTR), chemotherapy (60% with myeloablative therapy including stem cell rescue) and RT. For patients with M0 stage (n = 60), 50 (83%) had focal RT and 10 (17%) had CSI. Among patients with M + stage (n = 8), 3 had focal RT and 5 had CSI. Four-year overall survival (OS, n = 68) was 56% with no differences observed between M0 and M + stage patients (p = 0.848). Local Control (LC) at 4 years did not show a difference for lower primary dose (50–53.9 Gy) compared to ≥ 54 Gy (73.3% vs 74.7%, p = 0.83). For patients with M0 disease, four-year OS for focal RT was 54.6% and for CSI was 60% (Hazard Ratio 1.04, p = 0.95. Four-year event free survival (EFS) among M0 patients for focal RT was 45.6% and for CSI was 60% (Hazard Ratio 0.71, p = 0.519). For all patients, the 4-year OS comparing focal RT with CSI was 54.4% vs 60% respectively (p = 0.944), and the 4-year EFS for focal RT or CSI was 42.8% vs 51.4% respectively (p = 0.610). Conclusion: The PPCR ATRT cohort found no differences in outcomes according to receipt of either higher primary dose or larger RT field (CSI). However, most patients were M0 and received focal RT. A lower primary dose (50.4 Gy), regardless of patient age, is appealing for further study as part of multi-modality therapy.
KW - ATRT
KW - Atypical teratoid/rhabdoid tumor
KW - Brain
KW - Pediatric
KW - Proton
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85150590043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150590043&partnerID=8YFLogxK
U2 - 10.1007/s11060-023-04296-5
DO - 10.1007/s11060-023-04296-5
M3 - Article
C2 - 36951945
AN - SCOPUS:85150590043
SN - 0167-594X
VL - 162
SP - 353
EP - 362
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 2
ER -